Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption
about
How can mathematical models advance tuberculosis control in high HIV prevalence settings?Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinumA multi-scale approach to designing therapeutics for tuberculosisA computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatmentTreatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsyClassic reaction kinetics can explain complex patterns of antibiotic action.Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsHandling data below the limit of quantification in mixed effect models.Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetesPharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIVPopulation pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailabilityGenetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant periodA pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--using rifampicin as an example.Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Population pharmacokinetics of ethambutol in South African tuberculosis patients.A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variabilityA sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosetsPharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIVCan the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosisInfection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic ExtractionPopulation Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.A physiologically based pharmacokinetic model of rifampin in mice.The chemotherapy of tuberculosis: past, present and future.Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.Adequacy of Rifampin Absorption after Jejunostomy Tube Administration.Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
P2860
Q26824057-4BF34ECA-1F31-4B57-9E8C-319DAE8701B2Q28478890-F30E1EE2-75FA-4AA6-926D-CD0D8E2C98E2Q28647309-41E1304E-CA25-48CB-A2E5-35B849C52A82Q28649754-974AB6D1-2501-49F0-B02F-6C220D9259D6Q30383012-6EA2BE53-6934-41F4-B9D4-0A69F4AB82DFQ30405534-168BC39E-55BF-4D86-B092-5F664500AC20Q30662980-CAA47D3C-ADE5-4D08-82A8-82C23D41874EQ31041943-73DCCBBC-D809-4750-8483-B6010F064B78Q33447430-134CFDFC-4A9A-4F5A-A22B-EF8CB3ECE869Q33521011-92C11C05-FB3B-4B24-84E0-A810D7509EE1Q33797850-B09B9C0C-9C23-44E4-A367-9CCE064DA00BQ33797999-5A6DF86D-4F79-4B7A-BDE7-47BAC5CD8B67Q33798061-22AFD49F-CCDE-4B39-872C-FED97CB0541BQ33843657-56524A6C-A6C6-4BF1-A160-60F9F8C2D186Q34570937-FF629BE5-3E32-4D0B-8291-52F606505997Q35097554-58B5BD83-4E76-4A35-81AE-316176C648D9Q35120591-9DAA807C-2321-4F12-8BA0-09200B0B5CE1Q35191432-DB0224CA-74A0-4703-801F-D9C8CAF41B1DQ35191463-22742632-7F93-46FD-9F21-C610F39750EAQ35242238-BDEDC7BE-46FB-4C16-B702-866D6AFEABCCQ35532853-6FAD2228-9406-4681-BED1-EF7B1BEFFFA8Q35745991-1EF846A9-46D3-4201-9DC4-33A94502F6EAQ35859862-CFB31F28-6CAD-4615-89A0-125F3EEED625Q35867335-62610EF8-6EC0-4C35-A007-C48059306BBBQ35941434-03A846DC-54D0-43C2-BCEE-026F7D7E20B8Q36157986-850E4493-E3A4-4F4D-A933-3BA08ED813A9Q36171524-6F3F47E3-FA7D-49E0-8D14-44849F4F45ACQ36171653-57E4E1C5-149B-40BA-9C70-EA0FC9808928Q36438900-8619DEB6-A711-4D7B-B5B2-C432F7797501Q36644907-518A6FFA-CFE8-46E7-95F1-AEC7BEE98625Q36706812-06D73D61-7D83-48B9-B1DA-918936404004Q36728151-2E4502EB-7D9E-454E-835C-05FE5CC2B18EQ36757635-D558740D-E95E-4452-8F18-FA1283D7BAF0Q37076746-1CDD1D26-B09B-44DF-AACE-50B38966AE92Q37120112-4D5D7246-7444-4C6A-AA48-EEB5FB8AC8CDQ37124090-30D56248-0440-4B87-A462-634DC9E40DABQ37247736-319FD189-5B2F-44B2-9409-86A9EFB8FF17Q37287701-E22061E0-D99B-446F-8532-9E13276CCFC5Q37352344-9687145E-285A-4523-A4C3-2F6D7B194509Q37611687-98E58A48-DC76-4B18-A2F4-23FB9129ECF4
P2860
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Population pharmacokinetics of ...... o describe variable absorption
@ast
Population pharmacokinetics of ...... o describe variable absorption
@en
type
label
Population pharmacokinetics of ...... o describe variable absorption
@ast
Population pharmacokinetics of ...... o describe variable absorption
@en
prefLabel
Population pharmacokinetics of ...... o describe variable absorption
@ast
Population pharmacokinetics of ...... o describe variable absorption
@en
P2093
P2860
P50
P356
P1476
Population pharmacokinetics of ...... o describe variable absorption
@en
P2093
Goonaseelan Pillai
Grant Langdon
Mats O Karlsson
Peter J Smith
Radojka M Savic
P2860
P304
P356
10.1128/AAC.00461-07
P407
P577
2008-04-07T00:00:00Z